An update from Axsome Therapeutics ( ($AXSM) ) is now available. On April 1, 2026, Axsome Therapeutics announced an asset purchase agreement to acq......

TD Cowen analyst reiterated a Buy rating on Axis Capital today and set a price target of $130.00. In a report released on March 13, KBW also mainta......

In a report released today, Yatin Suneja from Guggenheim maintained a Buy rating on Axsome Therapeutics, with a price target of $245.00. According ......

NAXS AB ( ($SE:NAXS) ) has shared an update. NAXS AB has continued to execute its recently launched share repurchase program, buying back 1,936 sha......

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM), Monte Rosa Therapeutics ......

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolyPid (PYPD) and Axsome Therapeutics (AXSM) with b......

NAXS AB ( ($SE:NAXS) ) just unveiled an update. NAXS AB has initiated a share buyback programme authorized at its 2026 annual general meeting, allo......

The latest update is out from NAXS AB ( ($SE:NAXS) ). NAXS AB’s Annual General Meeting approved the 2025 accounts and a dividend of SEK 2.00 per sh......

Growth stocks are companies whose sales and earnings are expected to grow faster than the market average, and investors buy them for their future p......

An announcement from NAXS AB ( ($SE:NAXS) ) is now available. NAXS AB has continued to execute on its share repurchase program, buying back 5,645 s......